Scott J. Swanson, MD

home / authors / scott-j-swanson-md

Articles

Face-Off: Award Presentations and Event Conclusion

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

January 4th 2024

Judy concludes the event and presents the awards.

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

January 4th 2024

A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.

Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 28th 2023

Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.

Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 28th 2023

Dr. Herbst discusses the CHRYSALIS Phase 1 trial.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 21st 2023

An overview of results from the phase III randomized ADAURA Trial.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 21st 2023

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 14th 2023

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 14th 2023

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 7th 2023

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

December 7th 2023

Highlight on the debate format, speakers, and direction to support the discussion.

Minimally Invasive Surgery for Early-Stage Lung Cancer: From Innovation to Standard of Care

Abby White, DO;Scott J. Swanson, MD

November 15th 2016

This review highlights those efforts and the role of minimally invasive surgery for early-stage lung cancer in light of evolving technology, the emerging understanding of the biology of early-stage lung cancer, and lung cancer screening.